Scholar Rock (NASDAQ:SRRK) Insider Sells 9,035 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Caryn Parlavecchio sold 9,035 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $420,398.55. Following the completion of the sale, the insider owned 169,087 shares of the company’s stock, valued at approximately $7,867,618.11. The trade was a 5.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Caryn Parlavecchio also recently made the following trade(s):

• On Friday, January 16th, Caryn Parlavecchio sold 6,600 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total value of $293,568.00.

Scholar Rock Price Performance

Shares of SRRK traded up $0.74 during mid-day trading on Thursday, hitting $47.70. The company’s stock had a trading volume of 960,100 shares, compared to its average volume of 1,005,770. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $49.82. The firm has a market capitalization of $4.87 billion, a P/E ratio of -15.14 and a beta of 0.67. The firm has a 50-day simple moving average of $45.12 and a 200 day simple moving average of $38.23.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright boosted their target price on shares of Scholar Rock from $44.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. UBS Group started coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price objective on the stock. Wolfe Research assumed coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Finally, Citigroup started coverage on Scholar Rock in a report on Friday, January 9th. They set a “buy” rating and a $55.00 price objective for the company. Four research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $51.14.

Institutional Trading of Scholar Rock

A number of large investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its stake in Scholar Rock by 609.3% in the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after purchasing an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after buying an additional 5,831 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after buying an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after acquiring an additional 34,594 shares during the last quarter. Finally, Strs Ohio purchased a new stake in Scholar Rock in the 1st quarter worth approximately $77,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).